Background: The immune response to vaccination in hemodialysis (HD) patients can be influenced by disorders of iron metabolism, iron overload or chronic inflammatory state. Elevated levels of hepcidin are considered a new marker of iron metabolism impairment and anemia of inflammation in HD patients. Methods: We studied the effects of hepcidin, other markers of iron status and intravenous iron (Feiv) on the response to an influenza vaccine (Influvac® subunit 2008/2009) in 40 HD patients. The immune response of HD patients was compared with that of 46 controls without renal disease according to serum antihemagglutinin antibody titer (anti-HA). Results: A total of 31 HD patients (responders) attained seroconversion (at least a 4-fold increase in anti-HA) to at least 1 of 3 vaccine strains; 9 patients (nonresponders) did not respond to any strain. Responders did not differ from nonresponders in hepcidin [99 µg/l (36–200) vs. 97 µg/l (23–216), p = 0.97]. Responders had lower ferritin (571 ± 291 vs. 821 ± 309 µg/l, p = 0.031) and were administered higher doses of Feiv within the last 12 weeks prior to vaccination [625 mg (312–625) vs. 312 mg (0–625), p = 0.029]. The seroconversion to A(H1N1), A(H3N2) and B strains was noted in 20, 52 and 40% of HD and in 11, 39 and 48% of controls, respectively (HD vs. controls, p = nonsignificant). The rates of seroprotection (anti-HA ≧40) to vaccine strains in HD (27, 85 and 95%) and controls (24, 96 and 98%) were also comparable. Conclusion: Antibody production following influenza vaccination in HD patients may be suppressed by very high ferritin levels. Hepcidin does not correlate with immune response and high levels of hepcidin may reflect its retention in HD patients. Feiv administration was not associated with a poorer immune response. The immunogenicity of the A(H1N1) strain was inadequate in HD patients and controls alike.

1.
Pesanti EL: Immunologic defects and vaccination in patients with chronic renal failure. Infect Dis Clin North Am 2001;15:813–832.
2.
Kell DB: Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics 2009;2:2.
3.
Parkkinen J, von Bonsdorff L, Peltonen S, Grönhagen-Riska C, Rosenlöf K: Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant 2000;15:1827–1834.
4.
Teehan GS, Bahdouch D, Ruthazer R, Balakrishnan VS, Snydman DR, Jaber BL: Iron storage indices: novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. Clin Infect Dis 2004;38:1090–1094.
5.
Ganz T: Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003;102:783–788.
6.
Ganz T: Molecular control of iron transport. J Am Soc Nephrol 2007;18:394–400.
7.
Palmer DF, Dowle WR, Coleman MT, Schild GC: Advanced laboratory technicals for immunological diagnostic. Immunology ser No 6, Procedural guide. 2. Hemagglutination-inhibition test. Atlanta, US Dept Hlth Ed Welfare, PHS, 1975, pp 25–62.
8.
Committee for Proprietary Medicinal Products: Note for guidance on harmonisation of requirements for influenza vaccines (revision). London, CPMP/BWP/214/96, 1997, pp 1–18.
9.
Gilbertson DT, Unruh M, McBean AM, Kausz AT, Snyder JJ, Collins AJ: Influenza vaccine delivery and effectiveness in end-stage renal disease. Kidney Int 2003;63:738–743.
10.
Song JY, Cheong HJ, Ha SH, Kee SY, Jeong HW, Kim WJ: Active influenza immunization in hemodialysis patients: comparison between single-dose and booster vaccination. Am J Nephrol 2006;26:206–211.
11.
Cavdar C, Sayan M, Sifil A, Artuk C, Yilmaz N, Bahar H, Camsari T: The comparison of antibody response to influenza vaccination in continuous ambulatory peritoneal dialysis, hemodialysis and renal transplantation patients. Scand J Urol Nephrol 2003;37:71–76.
12.
Antonen JA, Hannula PM, Pyhälä R, Saha HH, Ala-Houhala IO, Pasternack AI: Adequate seroresponse to influenza vaccination in dialysis patients. Nephron 2000;86:56–61.
13.
Vogtländer NP, Brown A, Valentijn RM, Rimmelzwaan GF, Osterhaus AD: Impaired response rates, but satisfying protection rates to influenza vaccination in dialysis patients. Vaccine 2004;22:2199–2201.
14.
Tanzi E, Amendola A, Pariani E, Zappa A, Colzani D, Logias F, Perego A, Zanetti AR: Lack of effect of a booster dose of influenza vaccine in hemodialysis patients. J Med Virol 2007;79:1176–1179.
15.
Beyer WE, Versluis DJ, Kramer P, Diderich PP, Weimar W, Masurel N: Trivalent influenza vaccine in patients on haemodialysis: impaired seroresponse with differences for A-H3N2 and A-H1N1 vaccine components. Vaccine 1987;5:43–48.
16.
Scharpé J, Peetermans WE, Vanwalleghem J, Maes B, Bammens B, Claes K, Osterhaus AD, Vanrenterghem Y, Evenepoel P: Immunogenicity of a standard trivalent influenza vaccine in patients on long-term hemodialysis: an open-label trial. Am J Kidney Dis 2009;54:77–85.
17.
Ahluwalia N, Sun J, Krause D, Mastro A, Handte G: Immune function is impaired in iron-deficient, homebound, older women. Am J Clin Nutr 2004;79:516–521.
18.
Walker EM Jr, Walker SM: Effects of iron overload on the immune system. Ann Clin Lab Sci 2000;30:354–365.
19.
Richardson D: Clinical factors influencing sensitivity and response to epoetin. Nephrol Dial Transplant 2002;17(suppl 1):53–59.
20.
Zandman-Goddard G, Shoenfeld Y: Ferritin in autoimmune diseases. Autoimmun Rev2007;6:457–463.
21.
Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, Zazra JJ, Anandan JV, Gupta A: Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000;11:530–538.
22.
Chang CH, Chang CC, Chiang SS: Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients. Clin Nephrol 2002;57:136–141.
23.
DeVita MV, Frumkin D, Mittal S, Kamran A, Fishbane S, Michelis MF: Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. Clin Nephrol 2003;60:335–340.
24.
KDOQI; National Kidney Foudnation: II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 2006;47(suppl 3):S16–S85.
25.
Liu JH, Liu YL, Lin HH, Yang YF, Kuo HL, Lin PW, Huang CC: Intravenous iron attenuates post-vaccination anti-HBsAg titres after quadruple hepatitis B vaccination in dialysis patients with erythropoietin therapy. Int J Clin Pract 2009;63:387–393.
26.
Patruta SI, Edlinger R, Sunder-Plassmann G, Hörl WH: Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 1998;4:655–663.
27.
Weiss G, Meusburger E, Radacher G, Garimorth K, Neyer U, Mayer G: Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int 2003;64:572–578.
28.
Kaltwasser JP, Kessler U, Gottschalk R, Stucki G, Möller B: Effect of recombinant human erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritis. J Rheumatol 2001;28:2430–2436.
29.
Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J: Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090–2093.
30.
Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, Taube DH, Bloom SR, Tam FW, Chapman RS, Maxwell PH, Choi P: Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 2009;75:976–981.
31.
Tomosugi N, Kawabata H, Wakatabe R, Higuchi M, Yamaya H, Umehara H, Ishikawa I: Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood 2006;108:1381–1387.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.